Action Biodexa Pharmaceuticals - BDRX

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

3,12

Prix Achat

2,90

Prix Vente

3,12

Volume échangé

25 333

2,90 Fourchette du Jour 3,11

0,00 Plage de 52 semaines 0,00

Cap du marché

1,812M

Clôture Veille

3,11

Ouverture

3,11

Dernière Transaction

3.1

Dernière heure de transaction

Volume financier

US$ 76 701

VWAP

3,0277

Volume moyen (3 m)

Actions en circulation

580 840

Rendement du Dividende

Ratio Cours sur Bénéfices

0,00

Bénéfice par action (BPA)

Chiffre d'affairess

381k

Bénéfice net

-7,08M

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, in Phase 3 development for Familial Adenomato... Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, in Phase 3 development for Familial Adenomatous Polyposis; tolimidone, in Phase 2 development for the treatment of type 1 diabetes; and MTX110, in Phase 1 development in aggressive rare/orphan brain cancer indications. Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.midatechgroup.com

Siège social

Cardiff, Gbr

Fondé

Biodexa Pharmaceuticals PLC est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker BDRX. Le dernier cours de clôture d'Biodexa Pharmaceuticals était de US$3,11. Au cours de la dernière année, les actions de Biodexa Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Biodexa Pharmaceuticals compte actuellement 580 840 actions en circulation. La capitalisation boursière d'Biodexa Pharmaceuticals est de US$1,81 million.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

BDRX - Frequently Asked Questions (FAQ)

What is the current Biodexa Pharmaceuticals share price?

The current share price of Biodexa Pharmaceuticals is US$ 3,12

How many Biodexa Pharmaceuticals shares are in issue?

Biodexa Pharmaceuticals has 580 840 shares in issue

What is the market cap of Biodexa Pharmaceuticals?

The market capitalisation of Biodexa Pharmaceuticals is USD 1,81M

What is the 1 year trading range for Biodexa Pharmaceuticals share price?

Biodexa Pharmaceuticals has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the reporting currency for Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals reports financial results in GBP

What is the latest annual turnover for Biodexa Pharmaceuticals?

The latest annual turnover of Biodexa Pharmaceuticals is GBP 381k

What is the latest annual profit for Biodexa Pharmaceuticals?

The latest annual profit of Biodexa Pharmaceuticals is GBP -7,08M

What is the registered address of Biodexa Pharmaceuticals?

The registered address for Biodexa Pharmaceuticals is 1 CASPIAN POINT, CASPIAN WAY, CARDIFF, CF10 4DQ

What is the Biodexa Pharmaceuticals website address?

The website address for Biodexa Pharmaceuticals is www.midatechgroup.com

Which industry sector does Biodexa Pharmaceuticals operate in?

Biodexa Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ABLVAble View Global Inc	US$ 1,73 (137,18%)	5,14M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
DWTXDogwood Therapeutics Inc	US$ 6,63 (49,66%)	25,92M
KZIAKazia Therapeutics Ltd	US$ 1,1899 (40,80%)	4,5M
ALBTAvalon GloboCare Corporation	US$ 6,96 (-36,15%)	577,55k
SCNXScienture Holdings Inc	US$ 1,55 (-35,68%)	1,59M
ACXPAcurx Pharmaceuticals Inc	US$ 0,4572 (-29,88%)	1,18M
RETOReTo Eco Solutions Inc	US$ 5,42 (-27,73%)	108,27k
OCTOEightco Holdings Inc	US$ 1,08 (-27,03%)	336,99k
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
NVDANVIDIA Corporation	US$ 112,69 (1,92%)	341,94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,675 (-0,70%)	143,04M
ICONIcon Energy Corporation	US$ 0,169898 (17,17%)	142,23M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biodexa Pharmaceuticals PLC (BDRX)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Biodexa Pharmaceuticals PLC

BDRX Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

BDRX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Biodexa Pharmaceuticals PLC (BDRX) Cours

Biodexa Pharmaceuticals PLC (BDRX)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Biodexa Pharmaceuticals PLC

BDRX Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

BDRX - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR